After a thorough and comprehensive review of proposals received from suppliers of viral marker testing platforms and assays, CTS has decided to convert to the Ortho VERSEIA Integrated Processor (VIP) viral marker testing platform and associated assays in January 2021. An exact conversion date will be provided when available. We are confident that the VERSIA system will allow us to continue delivering on our commitment to support our clients in their life-saving mission.
Read all about it on the Communication page by clicking this link: Communications
On July 6, 2018 the FDA released an industry guidance document for transitioning from individual to ...
On February 18, 2019, the new CTS Laboratory Information System was successfully implemented in Tamp...
We sincerely hope to see you at this year’s AABB Annual Meeting in San Antonio, TX on October ...
The CTS 2020 Annual Laboratory Survey is on its way to your email box. We would appreciate you takin...
This is the first update to the original CTS communication distributed on July 6th. As previously co...
CTS Charlotte Lab successfully implemented WNV NAT testing on the Panther Testing Platform on Monday...